369 related articles for article (PubMed ID: 15008984)
1. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.
Walker LJ; Aldhous MC; Drummond HE; Smith BR; Nimmo ER; Arnott ID; Satsangi J
Clin Exp Immunol; 2004 Mar; 135(3):490-6. PubMed ID: 15008984
[TBL] [Abstract][Full Text] [Related]
2. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.
Papp M; Altorjay I; Norman GL; Shums Z; Palatka K; Vitalis Z; Foldi I; Lakos G; Tumpek J; Udvardy ML; Harsfalvi J; Fischer S; Lakatos L; Kovacs A; Bene L; Molnar T; Tulassay Z; Miheller P; Veres G; Papp J; ; Lakatos PL
Inflamm Bowel Dis; 2007 Aug; 13(8):984-92. PubMed ID: 17417801
[TBL] [Abstract][Full Text] [Related]
3. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Papp M; Altorjay I; Dotan N; Palatka K; Foldi I; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Norman GL; Szamosi T; Papp J; ; Lakatos PL
Am J Gastroenterol; 2008 Mar; 103(3):665-81. PubMed ID: 18047543
[TBL] [Abstract][Full Text] [Related]
4. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.
Cruyssen BV; Peeters H; Hoffman IE; Laukens D; Coucke P; Marichal D; Cuvelier C; Remaut E; Veys EM; Mielants H; De Vos M; De Keyser F
Clin Exp Immunol; 2005 May; 140(2):354-9. PubMed ID: 15807862
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease.
Dassopoulos T; Frangakis C; Cruz-Correa M; Talor MV; Burek CL; Datta L; Nouvet F; Bayless TM; Brant SR
Inflamm Bowel Dis; 2007 Feb; 13(2):143-51. PubMed ID: 17206688
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort.
Schoepfer AM; Schaffer T; Mueller S; Flogerzi B; Vassella E; Seibold-Schmid B; Seibold F
Inflamm Bowel Dis; 2009 Sep; 15(9):1358-67. PubMed ID: 19253375
[TBL] [Abstract][Full Text] [Related]
7. Higher titers of anti-Saccharomyces cerevisiae antibodies IgA and IgG are associated with more aggressive phenotypes in Romanian patients with Crohn's disease.
Gologan S; Iacob R; Preda C; Vadan R; Cotruta B; Catuneanu AM; Iacob S; Constantinescu I; Gheorghe L; Iobagiu S; Gheorghe C; Diculescu M
J Gastrointestin Liver Dis; 2012 Mar; 21(1):39-44. PubMed ID: 22457858
[TBL] [Abstract][Full Text] [Related]
8. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease.
Smith BR; Arnott ID; Drummond HE; Nimmo ER; Satsangi J
Inflamm Bowel Dis; 2004 Sep; 10(5):521-8. PubMed ID: 15472511
[TBL] [Abstract][Full Text] [Related]
9. Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn disease.
Russell RK; Ip B; Aldhous MC; MacDougall M; Drummond HE; Arnott ID; Gillett PM; McGrogan P; Weaver LT; Bisset WM; Mahdi G; Wilson DC; Satsangi J
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):161-7. PubMed ID: 19179877
[TBL] [Abstract][Full Text] [Related]
10. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study.
Annese V; Andreoli A; Andriulli A; Dinca R; Gionchetti P; Latiano A; Lombardi G; Piepoli A; Poulain D; Sendid B; Colombel JF
Am J Gastroenterol; 2001 Aug; 96(8):2407-12. PubMed ID: 11513182
[TBL] [Abstract][Full Text] [Related]
11. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.
Tung CC; Wong JM; Lee WC; Liu HH; Chang CH; Chang MC; Chang YT; Shieh MJ; Wang CY; Wei SC
J Gastroenterol Hepatol; 2014 Apr; 29(4):723-9. PubMed ID: 24783249
[TBL] [Abstract][Full Text] [Related]
12. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.
Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A
Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007
[TBL] [Abstract][Full Text] [Related]
13. Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease.
Klebl FH; Bataille F; Hofstädter F; Herfarth H; Schölmerich J; Rogler G
Int J Colorectal Dis; 2004 Jul; 19(4):319-24. PubMed ID: 14745572
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.
Lakatos PL; Altorjay I; Szamosi T; Palatka K; Vitalis Z; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Barta Z; Stocker W; Papp J; Veres G; Papp M;
Inflamm Bowel Dis; 2009 Mar; 15(3):365-74. PubMed ID: 18972554
[TBL] [Abstract][Full Text] [Related]
15. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn's disease in Tunisian population.
Marrakchi R; Bougatef K; Moussa A; Ouerhani S; Khodjet-el-Khil H; Messai Y; Mestiri O; Najar T; Benammar-Elgaaeid A
Inflamm Res; 2009 Apr; 58(4):218-23. PubMed ID: 19184350
[TBL] [Abstract][Full Text] [Related]
16. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.
Arnott ID; Landers CJ; Nimmo EJ; Drummond HE; Smith BK; Targan SR; Satsangi J
Am J Gastroenterol; 2004 Dec; 99(12):2376-84. PubMed ID: 15571586
[TBL] [Abstract][Full Text] [Related]
17. Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors.
Hadrich I; Vandewalle P; Cheikhrouhou F; Makni F; Krichen MS; Sendid B; Standaert-Vitse A; Ayadi A; Poulain D
Scand J Gastroenterol; 2007 Jun; 42(6):717-25. PubMed ID: 17505994
[TBL] [Abstract][Full Text] [Related]
18. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans.
Dassopoulos T; Nguyen GC; Talor MV; Datta LW; Isaacs KL; Lewis JD; Gold MS; Valentine JF; Smoot DT; Harris ML; Oliva-Hemker M; Bayless TM; ; Burek CL; Brant SR
Am J Gastroenterol; 2010 Feb; 105(2):378-86. PubMed ID: 19826411
[TBL] [Abstract][Full Text] [Related]
19. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis.
Makharia GK; Sachdev V; Gupta R; Lal S; Pandey RM
Dig Dis Sci; 2007 Jan; 52(1):33-9. PubMed ID: 17160471
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases.
Saibeni S; Folli C; de Franchis R; Borsi G; Vecchi M
Dig Liver Dis; 2003 Dec; 35(12):862-8. PubMed ID: 14703881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
